arrow_back Back to App

Streamlining Research for Breakthrough Medical Therapies

This act aims to accelerate research into new medications, especially those with potential for breakthrough treatments of serious diseases. It simplifies rules for conducting research on controlled substances, potentially leading to faster access to innovative therapies for patients.
Key points
Faster Research Approvals: Researchers can start studies on certain substances more quickly, speeding up new drug development.
Easier Team Collaboration: More individuals within research institutions can work on the same studies without needing separate permits.
Clear Rules for Breakthrough Substances: The act defines how substances with breakthrough therapy potential are handled, easing their study and potential market introduction.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_5123
Sponsor: Sen. Booker, Cory A. [D-NJ]
Process start date: 2022-11-17
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Breakthrough Therapies Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_5123.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-11-17.

What are the main provisions?

Key points include:

  • Faster Research Approvals: Researchers can start studies on certain substances more quickly, speeding up new drug development.
  • Easier Team Collaboration: More individuals within research institutions can work on the same studies without needing separate permits.
  • Clear Rules for Breakthrough Substances: The act defines how substances with breakthrough therapy potential are handled, easing their study and potential market introduction.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Booker, Cory A. [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Courts and Law